

### DAY 1 • THURSDAY, SEPTEMBER 24

6:30 am – 5:45 pm	Registration and Information Desk
7:00 am – 7:45 am	BREAKFAST • Industry Sponsored Product Theater
<b>SESSION 1: PROSTATE IMAGING</b>	
8:00 am – 8:05 am	Welcome
8:05 am – 8:25 am	Prostate MRI in 2026: Marks and Misses
8:25 am – 8:40 am	Not All MRIs Are Created Equal: The Hidden Variability of mpMRI
8:40 am – 8:50 am	Discussion
8:50 am – 9:00 am	Precision Diagnostics: The Next Generation of MRI-Guided Prostate Biopsy
9:00 am – 9:10 am	PSMA PET: Precision imaging or Precision Overdiagnosis?
9:10 am – 9:25 am	Signal or Noise? Rethinking Intraprostatic Tracer Uptake in PSMA Imaging
9:25 am – 10:00 am	Panel Discussion: Smarter Selection for Screening and Diagnosis with Imaging and Biomarkers
10:00 am – 10:30 am	COFFEE BREAK WITH EXHIBITORS
<b>SESSION 2: ARTIFICIAL INTELLIGENCE</b>	
10:30 am – 10:45 am	The Connected Urologist: AI, Robotics, and the Future of Procedural Care
10:45 am – 11:00 am	Bridging Radiologic Interpretation and Urologic Insight with AI in Prostate Imaging/Segmentation
11:00 am – 11:05 am	Discussion
11:05 am – 11:20 am	Can AI assess Surgical Skill? Operative Video to Outcomes
11:20 am – 11:35 am	Your Next Patient is Using AI -- Are you?
11:35 am – 11:45 am	Discussion
11:45 am – 12:20 pm	<b>KEYNOTE LECTURE • From Assistance to Autonomy: Building Intelligent Surgical Robots</b> <i>Michael Yip, PhD</i>
12:20 pm – 12:30 pm	Discussion
12:30 pm – 1:30 pm	LUNCH • Industry Sponsored Product Theater
1:30 pm – 5:45 pm	<b>ADVANCED PROSTATE CANCER MASTERCLASS FOR UROLOGISTS</b>
1:30 pm – 1:50 pm	Advanced Prostate Cancer: Key Concepts, Terminology, and Guideline Overview
1:50 pm – 2:10 pm	Integrating Systemic Therapy into Localized Prostate Cancer Care
2:10 pm – 2:30 pm	Local and Metastasis-Directed Therapy in the Era of Systemic Intensification
2:30 pm – 2:40 pm	Discussion
2:40 pm – 3:00 pm	Targeting the Androgen Axis: Therapeutic Agents and Adverse Effects
3:00 pm – 3:20 pm	Point Counterpoint: 73 yo M with denovo mCSPC, GG4, 5 bone mets seen on PSMA PET ADT+ ARPI ADT + ARPI+ Docetaxel
3:20 pm – 3:30 pm	Discussion
3:30 pm – 4:00 pm	COFFEE BREAK WITH EXHIBITORS
4:00 pm – 4:15 pm	Genetic Testing and Impact on Treatment Selection



### DAY 1 • THURSDAY, SEPTEMBER 24 *continued*

4:15 pm – 4:45 pm	Panel Discussion: Management of Low Volume PSMA Positive mets
4:45 pm – 4:55 pm	Parp Inhibitors for Prostate Cancer
4:55 pm – 5:15 pm	Radioligands in Advanced Prostate Cancer Management: Future Frontiers
5:15 pm – 5:35 pm	Emerging Therapeutic Targets in Prostate Cancer
5:35 pm – 5:40 pm	Discussion
5:40 pm – 5:45 pm	Conclusion

### DAY 2 • FRIDAY, SEPTEMBER 25

7:00 am – 6:00 pm	Registration and Information Desk
7:00 am – 7:45 am	BREAKFAST • Industry Sponsored Product Theater
<b>BPH MANAGEMENT COURSE</b>	
8:05 am – 8:05 am	Welcome and Speaker Introductions
8:05 am – 8:15 am	BPH in 2026: Guidelines, Updates & What's New
8:15 am – 8:25 am	MIST in 2026: Patient Selection & Practical Considerations
8:25 am – 8:35 am	Surgical BPH: Patient Selection & Practical Considerations
8:35 am – 8:40 am	Discussion
8:40 am – 9:20 am	Interactive Case Discussions <b>Case 1</b> BPH + Prostate Cancer — Combined or Sequential Treatment? <b>Case 2</b> Retention after Focal Therapy <b>Case 3</b> Small Prostate (30g) — Unique Challenges <b>Case 4</b> Younger Patient with BPH — Preserving Sexual Function <b>Case 5</b> Large Prostate (>100g) — MIST vs. Surgery
9:20 am – 9:30 am	Building a BPH Program: Key Infrastructure & Team Considerations
9:30 am – 9:40 am	Optimizing the BPH Clinical Pathway
9:40 am – 9:50 am	HoLEP Advances
9:50 am – 10:00 am	Discussion
10:00 am – 10:05 am	Conclusions & Closing Remarks
10:05 am – 10:35 am	COFFEE BREAK WITH EXHIBITORS
<b>BPH LIVE HANDS-ON LAB*</b>	
10:35 am – 12:00 pm	Live Hands-on Lab*
12:00 pm – 1:00 pm	LUNCH • Industry Sponsored Product Theater

### DAY 2 • FRIDAY, SEPTEMBER 25 *continued*

SESSION 3: INTRODUCTION TO FOCAL THERAPY	
1:00 pm – 1:15 pm	Rethinking the Rationale for Focal Therapy and Prostate Ablation
1:15 pm – 1:30 pm	Patient Selection: Are All Intermediate Risk Cancers Candidates for Ablation?
1:30 pm – 1:45 pm	Beyond MRI: The Value of Alternative Imaging in Patient Selection
1:45 pm – 1:55 pm	Discussion
1:55 pm – 2:10 pm	Getting the Right Tissue: Optimizing Biopsy for Decision-Making
2:10 pm – 2:25 pm	Genomic/AI Risk Classifiers in Focal Therapy Selection
2:25 pm – 2:30 pm	Discussion
2:30 pm – 2:40 pm	Guidelines Perspectives on Prostate Ablation
2:40 pm – 2:50 pm	Perspectives on Guidelines on Prostate Ablation
2:50 pm – 3:00 pm	Discussion
<b>3:00 pm – 3:30 pm</b>	<b>COFFEE BREAK WITH EXHIBITORS</b>
SESSION 4: FOCAL THERAPY TREATMENT	
3:30 pm – 4:00 pm	Panel Discussion: Multi-Disciplinary Tumor Board in Focal Therapy: Patient and Treatment Selection
4:00 pm 4:20 pm	Strengths and Limitations of Ablative Technologies
4:20 pm – 4:30 pm	What is the Optimal Margin for Treatment?
4:30 pm – 4:35 pm	Discussion
4:35 pm – 5:25 pm	<b>BALLOON DEBATE</b> 82yo M Gleason 4+3 High Volume, Higher Volume GG1 Other Side, High Genomic Risk, PSA 14, 52g Prostate, LUTS Mild
	Hemiablation
	Active Surveillance/Watchful Waiting
	Radiation Therapy (with/without ADT)
	Whole Gland Ablation
	TBD ? – Sandeep Gurram
<b>5:30 pm – 6:00 pm</b>	<b>POSTER SESSION</b>
<b>WELCOME RECEPTION</b> 5:30 PM – 7:00 PM	

### DAY 3 • SATURDAY, SEPTEMBER 26

6:45 am – 4:15 pm	Registration and Information Desk
7:00 am – 8:00 am	BREAKFAST • Industry Sponsored Product Theater
<b>SESSION 5: FOCAL THERAPY SURVEILLANCE AND CHALLENGES</b>	
8:00 am – 8:15 am	Can Focal Therapy Treatment Planning Tools Optimize Outcomes?
8:15 am – 8:30 am	After the Burn: Interpreting Imaging Following Prostate Ablation
8:30 am – 9:00 am	FTS Lecture: Defining Success and Failure After Focal Ablation: Imaging, PSA, and Biopsy
9:00 am – 9:10 am	Discussion
9:10 am – 9:30 am	Oral Abstract Presentations
9:30 am – 10:00 am	COFFEE BREAK WITH EXHIBITORS
10:00 am – 12:15 pm	Hands-on TP and Fusion Guided Ablation (4 rotations, 22 mins each)
12:15 pm – 1:00 pm	LUNCH
<b>SESSION 6: Prostate Precision</b>	
1:00 pm – 1:20 pm	Patterns of Failure After Focal Therapy and Their Management
1:20 pm – 1:35 pm	Salvage Radical Therapy After Focal Therapy Recurrence
1:35 pm – 2:10 pm	Case Discussions: Recurrence and Management
2:10 pm – 2:25 pm	Clinical Trials in Focal Therapy (in the last 12 months)
2:25 pm – 2:40 pm	Is Prostate Ablation an Option for Treatment of Select Higher Risk Prostate Cancers?
2:40 pm – 3:30 pm	Addressing the Critiques of Focal Therapy
	Prostate Cancer is Multifocal (index lesion)
	FT Has Poor Local Control and High Retreatment Rates
	Lack of Level 1 Evidence / Long Term Comparative Outcomes
3:30 pm – 3:50 pm	Beyond Treatment: Lifestyle Choices That Impact Prostate Cancer
3:50 pm – 4:00 pm	CPT Updates: Billing and Reimbursement for Fusion, Transrectal, and Transperineal biopsy
4:00 pm – 4:10 pm	Conclusion

# FOCAL<sup>+</sup>



FOCAL2026



focalcme.com